Time filter

Source Type

Grant
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: NMP-11-2015 | Award Amount: 8.29M | Year: 2016

PRECIOUS aims at scaling-up biodegradable nanomedicines for multimodal precision cancer immunotherapy. With 3.5 million cancer patients in Europe every year, new cancer medicines are eagerly awaited, notably for prostate and ovarian cancer. Systemically applied new immunotherapies are promising, but their toxicity is a hurdle. Vaccination against cancer is safe but rather disappointing: the microenvironment shuts down anti-tumour immunity. PRECIOUS will tackle 2 bottlenecks: 1. Production of non toxic multimodal nanomedicines, which induce vigorous immune responses, and at the same time reverse immunosuppression 2. Large scale GMP production of nanomedicines, and initiate multimodal immunotherapy Phase I trials. We want to solve these bottlenecks by: Objective 1: Two types of GMP biodegradable nanoparticles: 1) a nanovaccine, containing tumour antigens and immune activators, and 2) a nanoparticle composed of compounds, which reverses the suppression and reactivates immunity in the tumour. Objective 2: Clinical Phase I trials to show efficacy. Both nanomedicines will be used by 1) local delivery of vaccines in lymphnodes to evoke immune responses and 2) local injection of nanoparticles in the tumour microenvironment, which slowly release compounds that reverse suppression. To achieve this, a platform is formed with 6 leading industrial partners to produce large scale GMP nanomedicines and an excellent immunomodulator track record, together with 5 renowned academic partners to perform clinical studies. Local delivery will avoid toxicity, reduce dose, lower costs by 75%, and have major impact on the European health care system Relevance to call: Large scale GMP production, industrial leadership, nanotechnology and advanced manufacturing KET technologies, translation to the clinic, marketing development.


The food sector (including beverage industry) accounts for approximately two thirds of global packaging and about 50% of these packages are made of plastics. Plastic food packaging materials currently in use are generally non-biodegradable causing ecological imbalance and aesthetic deterioration of nature. At the same time being a petro-chemical based product, plastics rely on a depleting and increasingly costly natural resource with relatively low LCA performance (high CO2 footprint). Food packaging which is predominantly produced by SMEs - is crucial as physical and barrier protection keeping foodstuffs clean, fresh, and safe for consumers while increasing shelf life. Bio-based plastics offer a highly promising alternative and new biological materials are emerging as potential feedstock, such as chitin waste material from the fishing industry, mostly used in cosmetics applications due to their inherent bacteriostatic properties. Chitin waste exceeds 250 billion tons/year, and is considered hazardous due to its high perishability and polluting effect, both on land and sea. So re-use and up cycling to higher value applications would establish an important step forwards towards resource efficiency, providing a relevant innovation for the SME packaging industry that is under pressure to reduce cost and respond to environmental concerns. Recent research results at the University of Prague, leveraging on an SME owned world-wide patent (MAVI) for the production of chitin Nano fibrils, show interesting additional application opportunities of chitin as a bio-based polymer. The n-CHITOPACK project will leverage on the inherent superior properties of these chitin nano-fibrils for the development of new food packaging materials that are bacteriostatic, 100% bio-degradable and can be used by European packaging SMEs, contributing to increase their competitiveness in the market and to solving environmental challenges.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: NMP-2009-4.0-3 | Award Amount: 11.70M | Year: 2010

Medical diagnosis is currently undergoing a major revolution due to the fast discovery of molecular biomarkers, and the development of multimodal metabiomarker signatures. Progress, however, is hindered by low abundance of many biomarkers of interest in body fluids, in absolute concentration and with regard to other biomolecules. The aim of the present project is to apply these progresses in biotechnology, nanoparticle synthesis, and nano-instrumentation to the development of fully integrated lab-on chip instruments able to perform elaborate multimodal biomarker analysis on a routine basis and at the ultrasensitive level required to allow minimally invasive tests. In particular, we aim at overcoming a major bottleneck on the path to this objective, which was identified in a previous project in the HEALTH priority: no satisfactory solution currently exists to bridge the several orders of magnitude between the nanoscale volumes at which ultrasensitive new generation sensors operate, and the often millilitre volumes of samples in which the molecules of interest must be found. For this, we shall combine innovations in pre-concentration, micro and nanofluidics, self-assembly, micro-nanofabrication, and nanodetection. The project will develop a generic, multipurpose, platform of compatible enabling technologies, and integrate them into devices. In order to maximize impact and societal benefit, the project will be validated on an application of major interest for health, namely the early detection of biomarkers for neurodegenerative diseases (including Alzheimer), with special emphasis on subtyping of these diseases for improved treatment strategies. The consortium includes a multidisciplinary group of technology developers, three leading biomedical groups in clinical neuroscience for definition of specifications and end-user pre-clinical validation, and three research-oriented SMEs in biotechnology, nanosensing and microfluidics.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: NMP-2008-1.1-1 | Award Amount: 4.60M | Year: 2009

The project aims at developing a new integrated and automated microfluidic tool for cancer cells screening. This instrument will have a reliability and power much beyond state of the art (capture yield increased by a factor from 10X to 100X and multimodal typing of the cells in 3D high resolution images), allowing earlier and more accurate diagnosis, prognosis and selection of treatments of cancers. CaMiNEMSs new approach will involve a new generation of bio-functionalised multifunctional magnetic nano and microparticles which will be self-assembled by a Hierarchial Templated Self-Assembly mechanism into high-aspect ratio reversible arrays. For highly automated molecular typing of cancers, this key innovation will be integrated with a unique fully automated flow control system working from nanolitres to millilitres and with innovative nano-optics tools and image analysis software. Technological developments will be validated regarding the analysis of circulating tumour cells or micrometastases and the molecular typing of minimally invasive microsamples from tumours. The project will also yield new tools for research and drug-discovery, allowing for the first time to study at the single molecule scale in single cancer cells from patients the fate and action of new generation anticancer drugs using innovative dynamic tracking of Quantum dots. To combine research excellence and societal impact, the consortium involves research groups with complementary competences in microfluidics, nano-optics, biophysics, nanoparticles, biochemistry, informatics, several forefront cancer centres for clinical validation and a research-intensive SME for exploitation.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2010.1.2-1 | Award Amount: 6.55M | Year: 2010

A new generation of molecular tools is becoming available that can digitally record numbers, identities and locations of a broad range of molecular markers for increased diagnostic accuracy. This project will for the first time combine synergistically several groundbreaking technological innovations by the partners, notably padlock and proximity probes with rolling circle amplification for single molecule detection and counting, directed self-assembly of solid phases, and advanced microfluidics and read-out techniques, bringing these from the research lab into integrated instruments useful in routine. This will enable minimally invasive diagnostics, prognostics, and follow-up of treatment of cancers. Blood samples and fine needle aspirates will be subjected to high content, multiplex and multimodal assays of nucleic acids, proteins and interacting complexes thereof in single cells as well as in cell-free bodily fluids. We will use flow cytometry to collect multi-parameter information for large populations of cells, and individual detected molecules will be recorded using a fluorescence activated molecule counter developed by one of the partners. Also, very rare cells and molecules will be targeted through enrichment techniques using novel capturing approaches of unprecedented efficiency. We will apply these diagnostic approaches to characterize biomarkers in solid tumors and in leukemia and lymphoma for minimally invasive diagnostics, monitoring disease progress and selecting optimal therapy, and the assays will be clinically validated in small-scale studies of well-characterized patient samples. This project directly addresses four of the five topics in this call.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: ENERGY-2007-1.2-01 | Award Amount: 3.17M | Year: 2008

Hydrogen has the potential to provide a reliable, secure, and clean source of power. The barrier is the challenge of getting hydrogen economically to the point of use. Water electrolyser offers a practical way of hydrogen production in association with renewable energy sources. Compared to the conventional alkaline electrolyte electrolyser, the polymer electrolyte membrane (PEM) electrolyser can operate at high current densities and pressure with compact design. The main challenges for PEM electrolysers are high capital cost of key materials, components and the overall system as well as insufficient long-term durability. The strategic development of the WELTEMP project is an elevated operating temperature of the PEM electrolyser. In this way the energy efficiency will be significantly improved because of the decreased thermodynamic energy requirement, enhanced electrode kinetics, and the possible integration of the heat recovery. Key issues to achieve this strategic target are breakthroughs of fundamental materials developments, including catalysts, membranes, current collectors, bipolar plates, and other construction materials. The WELTEMP will start with developing active and stable anodic catalysts based on mixed metal oxides, temperature-resistant PEM based on composite PFSA, sulfonated aromatic and/or acid-base cross-linked polymers, and highly conducting and corrosion-resistant tantalum thin surface coatings as current collectors and bipolar plates. Based on these materials, a 1 kW prototype electrolyser will be constructed for demonstration and evaluation. It is aimed to reach operational temperature above 120C and a hydrogen production of 320 NL/h at 80% efficiency (LHV basis) at system level. These innovative developments need trans-national efforts from European industries and R&D groups. The expertise and know-how of the consortium in the field of refractory metals, electrocatalysts, polymers and membranes, MEA fabrication, and most importantly the construction and operation of water electrolysers, will ensure a success of the proposed project.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: GC.NMP.2013-1 | Award Amount: 11.49M | Year: 2013

Li-ion technologies initiated in the 90 at a fast development pace thanks mainly to emerging ICTs with more than 20 GWh sold in 2010. Soon, it appeared as a credible technology for electrical vehicles as it could provide average energy densities of about 140 Wh/kg. However and since then,major breakthroughs have been expected to reach higher storage levels of 250 Wh/kg on battery system level with an acceptable lifetime of 3000 cycles in order to develop an affordable economical business plan for car batteries. MAT4BAT builds-up its EVs battery strategy on advanced materials and pilot line processes, proposing three novel concepts of cells initiating from a state-of-the art combination of cell materials (NMC/Carbonate liquid electrolyte/Graphite). MAT4BAT will address all critical ageing mechanisms associated to this technology and having direct impacts on product lifetime & safety by implementing two work programs for Battery Assessment (#1) and Battery Technologies (#2). Program #1 will set a framework to define critical charging modalities for a battery system during practical use and associated testing tools & methods for relevant functional performance & lifetime assessment. Within this framework, the program #2 will implement three generations of cells with a focus on electrolytes which will be steadily transformed from Liquid to Gel to All-Solid state electrolytes in order to promote substantial gain in cell lifetime and safety by preventing degradations and hazards and improving energy density with a separator-free cell (all-solid state electrolyte). 100 state-of-the-art commercial cells will be assessed to define normal and critical charge/discharge conditions of testing with appropriate testing protocols. Besides,materials increments will be screened out on coin-cells prior a benchmarking of most promising materials at full cells level. Eventually,(10-40 A.h) prototypes will be produced to validate MAT4BAT best technologies against quantified objectives.


Grant
Agency: Cordis | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-ITN-2008 | Award Amount: 2.70M | Year: 2009

The large scale production of commodity polymers is increasingly shifting overseas. Europe still plays a major role in polymer processing and product development, but the competition with the US and Asia requires distinctive efforts to sustain this leadership. Thus, it is decisive for European researchers and companies to design innovative, specialised commodities and optimise current production strategies. NANOPOLYs main scientific objective is to further create, exchange and spread-out such know-how systematically within a European network in order to make this progress available and exploitable for European industries and coming generations of researchers. NANOPOLY will be unique in combining the strengths of applied mathematics/software engineering on the one hand and macro-molecular chemistry/reaction engineering on the other hand. These two sets of competences are currently rather unrelated but represent an important source of innovation for creating new models and associated software tools that permit new rational designs of polymer materials. NANOPOLYs main training objective is the education of a new generation of researchers who are able to bridge the still significant gap between the two mentioned sets of competences. The job market urgently calls for researchers with suchlike sophisticated knowledge and interdisciplinary training. These prospects will make participation in the network a rewarding career option. Through superior training, intense cooperation, and outreach the network will build-up an exeptional multi-disciplinary, European-based community that is able to achieve the crucial transfer of knowledge between the associated fields and thus permit major innovation in improving technological processes that allow tailoring nano-architectures of polymers to specific requirements.


In the NoE FlexNet, 17 participants from eleven European countries work together in order to support Europe in becoming a world leader in Flexible, Organic and Large Area Electronics (FOLAE). FlexNet aims at interlinking Europes FOLAE-expertise in the domains of science, technology development, components, devices and systems integration technologies. A special emphasis will be set on the subsequent commercial exploitation of FOLAE-based systems knowledge especially through SMEs, in order to enable a wide spread of FOLAE-based future business in Europe.\n\nThe NoE FlexNet will support the integration process of the scientific excellence of FOLAE-oriented European research on Materials, Devices and Systems. This part is complementary to the NoE PolyNet efforts. In addition, FlexNet will integrate excellent scientific capacities from Southern and Eastern Europe.\n\nFlexNet partners have identified the organic transistor as the most crucial building block in order to realised integrated organic systems. Therefore, the scientific focus of the NoE FlexNet will be set on the application of FOLAE-specific organic semiconductors as well as supporting materials for OTFTs including research on interface properties, barrier materials, characterisation, and OTFT device integration into systems. Further topics of dedicated attention and activity will be devices characterisation, systems integration, modelling and design of systems, and manufacturing processes for systems.\n\nAccordingly, NoE FlexNet will be structured in three platforms:\n- A platform FOLAE Materials and Devices Integration,\n- A platform Systems Integration and\n- A platform Knowledge, Dissemination and Transfer to industry\n\nThe knowledge associated to these topics will actively be made available to European stakeholders from research and industry, especially SMEs, in Southern and Eastern Europe. This will make FlexNet a bidirectional catalyst for information transfer in the FOLAE area between West-Central- and South-Eastern Europe.\n\nFlexNet will work in close contact with existing coordination actions in the FOLAE area like the Quadriga projects. This will ensure additional support in unifying and streamlining the fragmented FOLAE R&D arena in Europe.


Grant
Agency: Cordis | Branch: FP7 | Program: CSA-SA | Phase: NMP.2011.4.0-5 | Award Amount: 537.62K | Year: 2012

This proposal addresses the consolidation of the European Centre for Nanostructured Polymers - ECNP - which was established in 2006 by the European Network of Excellence NANOFUN-POLY (FP6 2004-2008) and is currently operating in coordinating research, dissemination and technology transfer activities among its partners. ECNP is focused on the continuation of the four main activities of the NoE: a joint research road map, a joint educational programme, a joint infrastructure and joint technology transfer services in the specific field of multifunctional nanostructured polymers and nanocomposites. So, this support action intends to consolidate ECNP offering a realistic financial plan to expand the current activities by ensuring coverage of industrial technologies research and transfer relevant to the main application sectors addressed by ECNP: Manufacturing (Polymer Nanocomposites), Energy (Flexible Photovoltaics), Healthcare (Biomaterials), and ensuring the extended participation of relevant industrial partners. It is expected that this support action will improve coordination in research and innovation on polymer nanotechnologies and will generate a more robust critical mass of the durable integrated structure of ECNP, leading to a better structuring of the European Research Area.

Loading Ustav makromolekularni chemie AV CR collaborators
Loading Ustav makromolekularni chemie AV CR collaborators